The Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030' report features an extensive study of the market for novel drugs, drug-device combinations and technologies for the treatment of back of the eye disorders. The focus of this study is on the applications and the likely evolution of novel treatment options (excluding steroids and corticosteroids) in the mid to long term.
Current projections also indicate that, in the US alone, the total economic burden related to vision loss is expected to reach approximately USD 715 billion by 2050. In fact, chronic eye diseases are considered to be one of the main causes of vision loss globally, and an estimated 90% cases of visual impairment are reported to be caused due to such conditions. It is worth highlighting that a significant portion of these chronic ophthalmological disorders are clinical conditions related to the back of the eye.
The current treatment landscape for back of the eye disorders is characterized by the presence of blockbuster drugs, such as Lucentis and Eylea, and various other therapeutic options. Despite the success of these therapies, their invasive mode of administration, high dosage frequency and other drug related side effects, are some of the drawbacks that have an adverse impact on their therapeutic potential and adoption. Further, there are no treatment approaches available for a number of ophthalmological indications, such as dry age related macular degeneration (dry AMD), retinitis pigmentosa (RP) and leber congenital amaurosis.
In order to overcome these challenges, various stakeholders are engaged in the development of novel therapeutic approaches. With the entry of several start-ups that are driving the innovation in this domain, the pipeline has several novel product candidates in various stages of development. Companies are steadily collaborating to develop and commercialize their products globally, in-license intellectual property to design new treatment modalities and advance research initiatives in this domain.
The evolving market has its hopes pinned on the efforts of multiple start-ups, small and large-sized companies. Amongst other elements, the report features:
A detailed assessment of the current market landscape of novel drugs, providing information on various drug / therapy developers, phase of development (clinical, preclinical or discovery stage) of product candidates, information on drug class, molecular target, type of therapy, mechanism of action, route of administration, and key therapeutic indication(s). In addition, we have provided a list of drug device combinations that target the back of the eye.
A world map representation, depicting the most active geographies in terms of the presence of companies developing drugs to treat back of the eye disorders.
A bull's eye analysis highlighting distribution of pipeline candidates in terms of phase of development, type of target and drug class. A grid analysis based on type of drug class developed / being developed across different indications and stages of development.
An elaborate discussion on lifecycle management strategies, depicting how companies are using various methods to expand patent exclusivity in order to exploit the revenue generation potential of their proprietary products.
Comprehensive profiles of clinical stage (phase II/III and above) drug candidates specifically targeting back of the eye disorders, highlighting their current status of development, mechanism of action, technology, patent portfolio, clinical trial information and recent developments.
A review of currently available technologies and delivery systems that are being used to administer therapeutics to the back of the eye, featuring brief profiles of the various technical advances, key benefits offered and information on the product candidates pipeline that are based on these technologies.
A discussion on various visual prosthesis that are available, highlighting their mechanism of action. In addition, we have provided a comparative 2X2 analysis of the different types visual prosthesis based on supplier power and product competitiveness.
An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, license agreements, mergers and acquisitions, manufacturing and services agreements, and other relevant agreements.
A discussion on the key promotional strategies that have been adopted for marketing approved drugs, namely (based on the approval year) Macugen, Lucentis, Eylea and Jetrea, that are presently prescribed to treat back of the eye disorders.
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2017-2030. To account for the uncertainties associated with the development of novel drugs and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.
Key Topics Covered:
1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION 3.1. Background and Context 3.2. Structure of the Eye 3.3. Components of Back of the Eye 3.4. The Visual Cycle 3.5. Barriers to the Back of the Eye 3.6. Route of Administration of Drugs to Back of the Eye 3.7. Disorders Associated with Back of the Eye 3.8. Treatment Options for Back of the Eye Disorders 3.9. Drug Delivery Platforms for Back of the Eye Disorders
4. COMPETITIVE LANDSCAPE 4.1. Chapter Overview 4.2. Back of the Eye Disorders: Clinical Pipeline 4.3. Back of the Eye Disorders: Preclinical/Discovery Pipeline 4.4. Back of the Eye Disorders Pipeline: Leading Players 4.5. Back of the Eye Disorders Pipeline: Most Prominent Hubs 4.6. Back of the Eye Disorders Pipeline: Regional Landscape 4.7. Back of the Eye Disorders Pipeline: Grid Analysis
6. DRUG PROFILES 6.1. Chapter Overview 6.2. LUXTURNA (Spark Therapeutics): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results 6.3. Sirolimus (Santen Pharmaceutical): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results 6.4. Abicipar Pegol (Molecular Partners/Allergan): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results 6.5. Brolucizumab (Alcon, a Division of Novartis): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results 6.6. GS010 (GenSight Biologics): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results 6.7. Lampalizumab (Roche): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results 6.8. Optina (Ampio Pharmaceuticals): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results 6.9. Squalamine (OHR Pharmaceutical): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results 6.10. Zuretinol (Novelion Therapeutics): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results 6.11. Zimura (Ophthotech): Mechanism of Action, Indication, Route of Administration, Molecular Target, Key Developments and Clinical Results
7. MARKET SIZE AND OPPORTUNITY ANALYSIS 7.1. Chapter Overview 7.2. Forecast Methodology and Key Assumptions 7.3. Overall Back of the Eye Disorders Market, 2017-2030 7.4. Back of the Eye Disorders Market: Distribution by Indications 7.5. Back of the Eye Disorders Market: Distribution by Drug Class 7.6. Back of the Eye Disorders Market: Distribution by Mechanism of Action 7.7. Back of the Eye Disorders Market: Distribution by Route of Administration
8. TECHNOLOGY PLATFORMS, DELIVERY SYSTEMS AND DRUG DEVICE COMBINATIONS 8.1. Chapter Overview 8.2. Drug Formulation Technologies 8.3. Drug Delivery Technologies/Systems 8.4. Drug Device Combinations/Implants
10. PARTNERSHIPS AND COLLABORATIONS 10.1. Chapter Overview 10.2. Partnership Models 10.3. Back of the Eye Disorders: List of Partnerships 10.4. Back of the Eye Disorders: Partnerships Analysis
13. CONCLUSION 13.1. The Back of the Eye Disorders Market is Characterized by a Robust Pipeline of Candidates Belonging to Different Drug Classes 13.2. Although Product Candidates are Being Developed to Treat a Number of Clinical Conditions, the Primary Focus is on Macular Degenerative Disorders 13.3. Increasing Partnerships Activity to Support Drug Development is Indicative of Future Opportunity 13.4. Currently, the Market is Led by Big Pharma Players; Many Start-ups, Though, are Making Significant Strides in this Domain 13.5. Multiple Novel Delivery Approaches are Being Investigated to Assist in Improving Patient Compliance 13.6. Given the Presence of Blockbuster Drugs, and Several Late Stage Product Candidates, the Market is Poised to Grow Steadily in the Foreseen Future
14. INTERVIEW TRANSCRIPTS 14.1. Chapter Overview 14.2. Elise Brownell, Senior Vice President of Operations and Project Management, Amarantus Bioscience 14.3. Quinton Oswald, President and CEO, Neurotech Pharmaceuticals 14.4 Samantha Cobb, CEO, AdAlta
15. APPENDIX: LIST OF DISCONTINUED MOLECULES
16. APPENDIX: TABULATED DATA
17. APPENDIX: LIST OF COMPANIES AND ORGANIZATIONS
Companies Mentioned
4D Molecular Therapeutics
AbbVie
Academy of Finland
Accredo Health Group
Achillion Pharmaceuticals
Aciont
ActiveSite Pharmaceuticals
Acucela
AdAlta
Adverum Biotechnologies
Aegerion Pharmaceuticals
Aerie Pharmaceuticals
Aerpio Therapeutics
Affilogic
AGTC
Alcon (a Novartis division)
Alfred Hospital
Alimera Sciences
Alkeus Pharmaceuticals
Allegro Ophthalmics
Allergan
Allinky Biopharma
ALTEOGEN
Amarantus BioScience
Amarna Therapeutics
Ampio Pharmaceuticals
Amyndas Pharmaceuticals
Apellis Pharmaceuticals
Apexian Pharmaceuticals
Apexigen
Apollo Endosurgery
Appletree CI Group
Araim Pharmaceuticals
Ascendis Pharma
AsclepiX Therapeutics
Astellas Institute for Regenerative Medicine (AIRM)
Astellas Pharma
Athena Vision
AyuVis Research
Bascom Palmer Eye Institute
Bausch + Lomb
Bayer
BCM Families Foundation
Benitec Biopharma
Besse Medical
Bicycle Therapeutics
BIOCND
Biogen
BioInvent
Biokine Therapeutics
BioLight Lifesciences
Bionic Sight
Bionic Vision Technologies (BVT)
BIOPHYTIS
BioTime
Biovista
Case Western Reserve University (CWRU)
Catalent
Catalyst Biosciences
Universit catholique de Louvain
Cellular Dynamics International (CDI)
Ceregene
Charlesson
Chengdu Kanghong Pharmaceuticals Group
Children's Hospital of Philadelphia
Cipla BioTec
Clanotech
Clearside Biomedical
Clonz Biotech
Coherus Biosciences
Columbia University
CoMentis
Copernicus Therapeutics
Critical Pharmaceuticals
CuraScript SD
CVS Caremark
Daiichi Sankyo
DelSiTech
Domp
Editas Medicine
Eleven Biotherapeutics
ElsaLys Biotech
Envisia Therapeutics
Exonate
EyeGate Pharma
Eyemedics
Eyetech Pharmaceuticals
Eyevensys
Ferrer
Fondation Voir et Entendre
Formycon
ForSight VISION 4
Foundation Fighting Blindness (FFB)
FUJIFILM Holdings
Galapagos
Galaxy Ophthalmics
Gemini Therapeutics
Genable Technologies
Gene Signal
Gene Techno Science
Genaera Corporation
Genentech
Genethon
GenSight Biologics
Gilead Sciences
Graybug Vision
Grey Innovation
GlaxoSmithKline (GSK)
Gunma University
Hadassah Medical Center
Hanmi Pharmaceutical
Harvard Medical School (HMS)
Healios
Hemera Biosciences
Henogen (a subsidiary of the Novasep group)
HORAMA
Huabo Biopharm
i2 Pharmaceuticals
Ichor Therapeutics
Icon Bioscience
Iconic Therapeutics
Illinois Institute of Technology
Inception Sciences
InFlectis BioScience
InnoCore Pharma
Innovent Biologics
Intas Pharmaceuticals
Intrexon
Ionis Pharmaceuticals
I'rom Group
Ixchel Pharma
Janssen
jCyte
Jeil Pharmaceutical
Jiangsu T-mab BioPharma
Johns Hopkins University
K.N. Toosi University of Technology
Kala Pharmaceuticals
Kalos Therapeutics
KalVista Pharmaceuticals
KMG Pharma
Kodiak Sciences
Kowa Company
Laboratoire de Gntique Mdicale de Strasbourg
LeadArtis
Lin Bio Science
Lonza
Loyola University Chicago
Lpath
Massachusetts General Hospital
Massachusetts Institute of Technology (MIT)
McKesson
Medical College of Wisconsin (MCW)
MeiraGTx
Memorial Sloan Kettering Cancer Center
Merck
MimeTech
Mimetogen Pharmaceuticals
MiniFAB
Mitotech
Molecular Partners
Monash University
MorphoSys
Mosaic Biosciences
M's Science Corporation
Mystic Pharmaceuticals
Nano Retina
Nanovision
National Institutes of Health (NIH)
Nektar Therapeutics
Neovacs
Neurotech Pharmaceuticals
NeXstar Pharmaceuticals
Novartis
Novelion Therapeutics
Ocata Therapeutics
OccuRx
Ocugen
Ocular Therapeutix
Oculis
OcuNexus Therapeutics
Odylia Therapeutics
Ohr Pharmaceutical
OliX Pharmaceuticals
Omeros
Opthea
Ophthotech
Opsis Therapeutics
Optobionics
Casey Eye Institute, Oregon Health & Science University (OHSU)
Osaka University
Oxford BioMedica
Oxular
Paloma Pharmaceuticals
Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse
PanOptica
Patheon
Pfenex
Pfizer
Pieris Pharmaceuticals
Pixium Vision
Polus
PolyActiva
Potentia Pharmaceuticals
Preceyes
ProLynx
Promedior
ProQR
Proretina Therapeutics
Proteostasis Therapeutics
pSivida
Qilu Pharmaceuticals
Quark Pharmaceuticals
Ra Pharma
Recursion Pharmaceuticals
Regeneron Pharmaceuticals
REGENXBIO
Reliance RX
ReNeuron
Replenish
Retina Foundation of the Southwest
Retina Implant
Retinagenix
RetroSense Therapeutics
Ribomic
Roche
Royal DSM
RWTH Aachen University
RXi Pharmaceuticals
Saksin Lifesciences
Samsung Bioepis
SanBio
Sanofi
Santen Pharmaceuticals
Santhera Pharmaceuticals
Santo Holding
SciFluor Life Sciences
Second Sight
Selexis
SENJU Pharmaceutical
SENS Research Foundation
SGS Life Science
Shanghai Jiao-Tong University
Sonikure Technology
Spark Therapeutics
Stanford University
Stealth BioTherapeutics
Sumitomo Dainippon Pharma
Sun Pharmaceutical
Syracuse University
Taiwan Liposome Company
Tanox
Massachusetts Eye and Ear Infirmary
The University of Manchester
University of Massachusetts Medical School
University of Pennsylvania
TheraKine
ThromboGenics
TRACON Pharmaceuticals
University of Tbingen
Tyrogenex
UCL Business
Universal Cells
University License Equity Holding (ULEHI), University of Colorado
About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada.
A media...
Targeting a Solution is an insightful and impactful fireside discussion dedicated to ending Veteran suicide that will have its next iteration on April 20th, 2024, in Kannapolis, NC hosted by The Independence Fund. The panel will feature four-term...
Equality Health Foundation, the philanthropic partner of Equality Health LLC and an organization dedicated to advancing health equity and improving well-being access for underserved communities, proudly announces its expansion into Virginia and...